Project Details
Description
DESCRIPTION (provided by applicant): WARCEF-STAT and WARCEF-CLIN are two highly coordinated units which together constitute WARCEF, a two-arm (1:1) double-blind randomized multicenter clinical trial. Its primary aim is to test the primary null hypothesis of no difference between warfarin (INR 2.5-3, target 2.75) and aspirin (325 mg/day) therapies in time to the first to occur of death from any cause, ischemic stroke, or symptomatic non-fatal intracerebral hemorrhage (ICH) among patients with low (
| Status | Finished |
|---|---|
| Effective start/end date | 9/30/01 → 8/31/13 |
Funding
- National Institute of Neurological Disorders and Stroke: US$5,534,164.00
- National Institute of Neurological Disorders and Stroke: US$2,081,306.00
- National Institute of Neurological Disorders and Stroke: US$1,000,000.00
- National Institute of Neurological Disorders and Stroke: US$2,043,118.00
- National Institute of Neurological Disorders and Stroke: US$1,684,927.00
- National Institute of Neurological Disorders and Stroke: US$2,168,405.00
- National Institute of Neurological Disorders and Stroke: US$200,000.00
- National Institute of Neurological Disorders and Stroke: US$2,607,698.00
- National Institute of Neurological Disorders and Stroke: US$1,995,081.00
- National Institute of Neurological Disorders and Stroke: US$1,982,994.00
ASJC Scopus Subject Areas
- Cardiology and Cardiovascular Medicine
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.